ExodusPoint Capital Management LP Has $445,000 Stake in Sana Biotechnology, Inc. (NASDAQ:SANA)

ExodusPoint Capital Management LP lifted its position in shares of Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) by 174.4% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 272,908 shares of the company's stock after purchasing an additional 173,442 shares during the quarter. ExodusPoint Capital Management LP owned about 0.12% of Sana Biotechnology worth $445,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB acquired a new stake in shares of Sana Biotechnology in the 3rd quarter valued at about $29,000. Blue Trust Inc. raised its position in shares of Sana Biotechnology by 51.0% during the 4th quarter. Blue Trust Inc. now owns 19,823 shares of the company's stock valued at $32,000 after acquiring an additional 6,694 shares in the last quarter. Ieq Capital LLC acquired a new position in Sana Biotechnology in the fourth quarter worth $32,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Sana Biotechnology during the fourth quarter worth $39,000. Finally, Stifel Financial Corp acquired a new position in shares of Sana Biotechnology in the 3rd quarter valued at about $43,000. Hedge funds and other institutional investors own 88.23% of the company's stock.

Analysts Set New Price Targets

Several research firms recently weighed in on SANA. Citizens Jmp raised shares of Sana Biotechnology from a "market perform" rating to an "outperform" rating and set a $5.00 price objective for the company in a report on Tuesday, March 18th. TD Cowen upgraded shares of Sana Biotechnology from a "hold" rating to a "buy" rating in a report on Wednesday, January 8th. HC Wainwright reaffirmed a "buy" rating and issued a $11.00 price objective on shares of Sana Biotechnology in a research note on Tuesday, March 18th. Finally, Jefferies Financial Group assumed coverage on Sana Biotechnology in a research report on Friday, March 14th. They issued a "buy" rating and a $7.00 price target for the company. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $10.80.

Sana Biotechnology Stock Up 4.4 %

SANA traded up $0.07 during trading on Friday, hitting $1.65. The company's stock had a trading volume of 1,350,508 shares, compared to its average volume of 3,298,112. The firm's 50 day moving average price is $2.27 and its two-hundred day moving average price is $2.75. The stock has a market capitalization of $371.29 million, a price-to-earnings ratio of -1.18 and a beta of 1.78. Sana Biotechnology, Inc. has a 12 month low of $1.26 and a 12 month high of $10.50.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last issued its quarterly earnings results on Monday, March 17th. The company reported ($0.23) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.02. On average, sell-side analysts forecast that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current year.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.